Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income/(loss) attributable to BioTime, Inc.	$ (30,032)	$ (4,215)	$ 9,278	$ (67,763)
Net loss allocable to noncontrolling interest	(20)	(431)	(34)	(581)
Adjustments to reconcile net income (loss) attributable to BioTime, Inc. to net cash used in operating activities:
Gain on sale of equity method investment in Ascendance				(3,215)
Acquired in-process research and development				800
Unrealized gain on marketable equity securities	607	(397)	(1,324)	(612)
Deferred income tax benefit	(1,248)		(5,632)
Depreciation expense, including amortization of leasehold improvements	244	279	513	560
Amortization of right-of-use asset			27
Amortization of intangible assets			992	1,164
Stock-based compensation	762	1,103	2,202	2,087
Change in fair value of liability classified warrants			(271)	(351)
Foreign currency remeasurement and other (gain) loss			(1,461)	1,137
Changes in operating assets and liabilities:
Accounts and grants receivable, net			(863)	(868)
Accrued interest receivable			(756)
Receivables from affiliates, net of payables			2,185	180
Prepaid expenses and other current assets			(1)	(259)
Accounts payable and accrued liabilities			(804)	(336)
Deferred revenue and other liabilities				(70)
Net cash used in operating activities			(18,981)	(17,738)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of equity method investment in Ascendance				3,215
Purchase of in-process research and development				(800)
Cash and cash equivalents acquired in the Asterias Merger			3,117
Purchase of equipment and other assets			(364)	(237)
Security deposit paid and other			(1)	(8)
Net cash provided by investing activities			2,752	2,170
CASH FLOWS FROM FINANCING ACTIVITIES:
Common shares received and retired for employee taxes paid			(77)	(13)
Reimbursement from landlord on tenant improvements			744
Repayment of principal portion of promissory notes			(70)
Proceeds from sale of common shares of subsidiary				5,000
Proceeds from sale of subsidiary warrants			(40)	737
Repayment of financing lease liabilities			(14)	(151)
Payment to repurchase subsidiary shares				(38)
Net cash provided by financing activities			543	5,535
Effect of exchange rate changes on cash, cash equivalents and restricted cash			83	(21)
NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH			(15,603)	(10,054)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH: At beginning of the period			24,399	37,685
CASH, CASH EQUIVALENTS AND RESTRICTED CASH: At end of the period	8,796	27,631	8,796	27,631
OncoCyte Corporation [Member]
Adjustments to reconcile net income (loss) attributable to BioTime, Inc. to net cash used in operating activities:
Unrealized (gain) loss on equity method investment	21,425	(6,603)	(16,288)	30,816
Asterias Biotherapeutics [Member]
Adjustments to reconcile net income (loss) attributable to BioTime, Inc. to net cash used in operating activities:
Unrealized (gain) loss on equity method investment		$ 2,175	$ (6,744)	$ 19,573